Sept. 22, 2011 - BCM-95® Curcumin and BosPure® Boswellia in a Clinical Study
GREEN BAY, WI, September 21, 2011— A combination of two patented herbal extracts, BCM-95 curcumin and BosPure boswellia, was judged superior to the prescription arthritis drug, celecoxib (the generic of the brand name Celebrex®) in a clinical study of osteoarthritis.1
The study was presented at the Osteoarthritis Research Symposium International (OARSI) in San Diego on September 16, 2011. The abstract will be published in their proceedings. OARSI is the premier international organization for scientists and health care professionals focused on the prevention and treatment of osteoarthritis through the promotion and presentation of research, education and the worldwide dissemination of new knowledge.
The BCM-95 curcumin and BosPure boswellia combination at 500 mg twice daily was better than celecoxib 100mg twice daily in relieving pain, walking distance and joint line tenderness scores. It was equally effective as celecoxib in alleviating crepitus, and range of joint movements. Efficacy and tolerability of the herbal combination used in the current study was shown to be superior to those of celecoxib (NSAID) for treating active osteoarthritis.
Subjects in this 12 week study were randomized to two groups. One group received celecoxib, 100 mg, twice daily and the second group received a 500 mg blend of BCM-95 curcumin and BosPure boswellia twice daily.
“We chose to examine BCM-95 because it has over 7 times the bioavailability of plain curcumin. The BosPure boswellia has a standardization of 10% or more acetyl-keto 11 beta-boswellic acid (AKBA) and very low beta boswellic acid (<5%). This standardization greatly improves the anti-inflammatory activity. In combination, these herbs complement one another and are highly effective,” stated Dr. Benny Antony, co-author of the study.
“Long-term non-steroidal inflammatory drug (NSAIDs) use is associated with gastrointestinal, kidney, and cardiovascular risks. These drugs can be dangerous. Some examples of NSAIDs are ibuprofen, aspirin, naproxen, celecoxib and diclofenac sodium. Given the efficacy, safety and tolerability issues associated with NSAIDs, development of new agents to manage OA without adverse events is a major priority,” Dr. Binu Kuruvilla, co-author of the study.
At the end of the study, 93% of the herbal treated subjects could walk more than 1000 meters vs. 86% in the drug group. 93% of the herbal group reported improvement in or elimination of pain vs. 79% of the drug group. There were no serious adverse events in the study. There were no significant changes in kidney or liver function, vital signs, or hemogram measures.
EuroPharma, Inc® is the exclusive distributor of BCM-95® curcumin and BosPure® boswellia products in the U.S. through both the health food store and professional distribution channels. Healthy Knees and Joints, a recently launched product in the Terry Naturally line of supplements, contains the blend of ingredients used in this study. EuroPharma offers clinically proven and effective nutritional supplements and natural remedies that improve the health of America. Terry Lemerond, founder and president of EuroPharma, is well-known for innovation, as he is credited as the first to introduce glucosamine sulfate, standardized Ginkgo biloba, and the award winning natural pain product, Curamin®, to the U.S. natural products market. At EuroPharma, Our Passion is Your Health®. For more information on EuroPharma and Terry Naturally products, visit www.EuroPharmaUSA.com
1. B. Antony, R. Kizhakkedath, M. Benny, B. Kuruvilla. Clinical Evaluation of an Herbal Formulation in the Management of Knee Osteoarthritis. Poster presentation. Presented at the Osteoarthritis Research Symposium Internationale (OARSI) Annual World Congress on Osteoarthritis, September 15-18, 2011. San Diego, CA.
EUROPHARMA USA LIBRARY DISCLAIMER
The research articles and study abstracts that you are about to view in the EuroPharma USA Library were prepared by independent authors and researchers. They are being reproduced on this site in their entirety. No such article or study abstract is intended to promote a particular manufacturer or brand of dietary supplement. This information is not intended to replace the advice of your health care practitioner. If you have any medical conditions, or are taking any prescription or nonprescription medications, see your physician and discuss all aspects of your treatment before altering or discontinuing any course of therapy. Accordingly, individuals must necessarily assume responsibility for their own actions, safety, and health, and the company is not liable or responsible for any loss, injury, or damage allegedly arising from any information posted on this cite.
THIS INFORMATION IS BEING PRESENTED PURSUANT TO SECTION 5 OF THE DIETARY SUPPLEMENT HEALTH AND EDUCATION ACT OF 1994-------THE "E" IN DSHEA—BROUGHT TO YOU AS A PUBLIC SERVICE BY EUROPHARMA USA.
